Antibody testing in patients treated with anti-CD38: there is still room for improvement
- PMID: 32697927
- PMCID: PMC7375888
- DOI: 10.2450/2020.0166-20
Antibody testing in patients treated with anti-CD38: there is still room for improvement
Conflict of interest statement
The Authors declare no conflicts of interest.
Comment on
-
New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing.Blood Transfus. 2020 Jul;18(4):290-294. doi: 10.2450/2020.0004-20. Epub 2020 Jun 4. Blood Transfus. 2020. PMID: 32530397 Free PMC article.
References
-
- Oostendorp M, Lammerts van Bueren JJ, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55:1555–62. - PubMed
-
- Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55:1545–54. - PubMed
-
- Carreno-Tarragona G, Cedena T, Montejano L, et al. Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies. Transfus Med. 2019;29:193–6. - PubMed
-
- Yeh TJ, Yeh CJ, Liu YC, Hsiao HH. Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma. Transfusion. 2019;59:2751–2. - PubMed
-
- Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;56:2964–72. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials